Indivior stock holds firm after record quarter and Supernus merger plan

Indivior Plc (GB00BYZ0C031) stock is trading at an elevated level after a record quarter and the announcement of a planned merger with Supernus, giving investors a fresh earnings and M&A story as of August 23, 2026.

Per a recent market overview dated August 24, 2026, the shares closed at $36.89 on August 23, 2026 with intraday trading between $36.72 and $38.52, putting the stock in the upper part of its recent trading range at a time when the broader market has been more cautious.

From a valuation perspective, the same overview indicates that based on the August 23, 2026 closing price of $36.89, Indivior currently trades on a price-earnings ratio of 13, signaling that investors are assigning a moderate multiple to its earnings despite strong operational momentum and the pending Supernus deal.

Record quarter sets the tone

According to a detailed earnings summary published on August 24, 2026, Indivior recently reported a record quarter, with revenue and profit reaching new highs for the latest reporting period and underlining the strength of its treatment portfolio.

The earnings commentary states that the most recent quarter delivered year-on-year revenue growth that outpaced many peers, and that operating profit expanded at a double-digit rate compared with the same quarter a year earlier, reflecting both higher sales volumes and disciplined cost control.

Management highlighted that this record quarter represents the strongest performance in the company’s history for that period, and that the combination of solid topline growth and improved margins has given the company more strategic flexibility as it moves into the planned Supernus merger.

Supernus merger plan adds strategic layer

The same report notes that the planned merger with Supernus is designed to broaden Indivior’s presence in neuroscience-related treatments and adjacent therapeutic areas, creating a more diversified revenue base once the transaction is completed.

The merger framework envisions combining Indivior’s established portfolio with Supernus’s pipeline and existing products, which, based on the latest quarter’s record results, could help sustain revenue growth and earnings power beyond the near term.

For investors, the key quantitative context is that the record quarter has given the company more earnings capacity at a time when it is preparing to integrate another business, which means that future comparisons will likely focus on how combined revenue and profit versus pre-merger levels evolve over the next several reporting periods.

Valuation, price levels and trading range

Market data in the August 24, 2026 overview show that Indivior’s shares traded between $36.72 and $38.52 on August 23, 2026, with the $36.89 close indicating that the stock finished the session slightly below its intraday high but still above the intraday low.

Using the August 23, 2026 closing price of $36.89 and the reported price-earnings ratio of 13, the implied earnings per share is in the range consistent with the record quarterly performance, underscoring that the market is not pricing the shares at a high-growth multiple despite recent operational strength.

The same commentary indicates that Indivior’s market capitalization stood at $4.6 billion as of the August 23, 2026 close, which means that every $1 move in the share price represents a meaningful shift in equity value and that the merger and record quarter together have created a larger platform than in prior years.

Earnings momentum and historical context

While the most recent quarter is described as a record, historical comparisons in the earnings review show that earlier fiscal periods had lower revenue and profit levels, with the current quarter exceeding those historical benchmarks both on a topline and bottom-line basis.

The earnings narrative notes that compared with an earlier fiscal year that served as a reference point, the current record quarter delivered a significantly higher revenue figure and stronger operating earnings, marking a clear progression in Indivior’s financial profile.

This quantified improvement relative to past performance helps explain why the shares are trading at an elevated level and why the company has chosen this moment to pursue a merger that could further shift the revenue and earnings mix in the coming years.

Treatment portfolio as a revenue driver

A key contributor to Indivior’s record quarter has been its portfolio of treatments for opioid use disorder and related conditions, which continue to generate sustained demand in core markets and underpin the company’s revenue growth.

The earnings discussion points out that higher prescription volumes and stable pricing have supported revenue expansion in the latest quarter, reinforcing the idea that Indivior’s core products remain competitive even as the company prepares to add Supernus’s assets to its lineup.

In future periods, investors will likely compare revenue and earnings from the combined treatment portfolio against the current record quarter to assess whether the merger is delivering the expected financial benefits and whether the price-earnings ratio remains aligned with the company’s growth trajectory.

Representative product: opioid use disorder therapies

One representative area of Indivior’s business is its range of opioid use disorder therapies, which are central to its mission and a key pillar of its revenue base.

These therapies are designed to help patients manage dependence and withdrawal, and the strong quarterly results suggest that demand for such treatments has remained robust in the latest reporting period, contributing to the record revenue and profit figures that have been highlighted.

Stock level and investor angle

As of August 23, 2026, Indivior’s stock closed at $36.89, and this price point, together with the reported trading range and market capitalization, gives investors a clear snapshot of the company’s market value ahead of the planned Supernus merger and in the wake of its record quarter.

The combination of a moderate price-earnings ratio of 13, a $4.6 billion market capitalization as of the latest close, and strong recent earnings performance suggests that the shares reflect both the company’s current profitability and the integration opportunity presented by the merger plan.

Fact box

Company: Indivior Plc

ISIN: GB00BYZ0C031

Ticker: INDV

Exchange: primary listing as indicated in recent market data

Price (as of August 23, 2026): $36.89

Market cap: $4.6 billion (as of August 23, 2026)

Sector / Industry: pharmaceuticals and biotechnology

Index membership: relevant home-market and sector indices